Blood cancers

Podcast: Minimal Residual Disease and why it’s important in ALL

Sponsored by Amgen Australia Pty Ltd

For acute lymphoblastic leukaemia (ALL) the level and timing of response to therapy can be a powerful tool in guiding therapeutic choice. Minimal Residual Disease (MRD) is an approach that aims to detect residual tumour cells beyond the threshold of conventional evaluation methods. In this podcast we’re joined on the phone by Professor Max Topp, ...

Already a member?

Login to keep reading.

© 2021 the limbic